Second Round Results of the Finnish Population-Based Prostate Cancer Screening Trial

Clinical Cancer Research

Volumn 10, Issue 7, 2004, Pages 2231-2236

  Mäkinen, Tuukka ^a   Tammela, Teuvo L J ^b   Stenman, Ulf Håkan ^c   Määttänen, Liisa ^d   Aro, Jussi ^c   Juusela, Harri ^e   Martikainen, Paula ^b   Hakama, Matti ^f   Auvinen, Anssi ^f  

^a SEINÄJOKI CENTRAL HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d FINNISH CANCER REGISTRY   (Finland)

^e JORVI HOSPITAL   (Finland)

^f UNIVERSITY OF TAMPERE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; FINLAND; FOLLOW UP; HIGH RISK POPULATION; HUMAN; MALE; MASS SCREENING; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL;

AGE FACTORS; AGED; ALGORITHMS; FINLAND; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 1842426687     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0338     Document Type: Article

References (23)

1. WHO. World health statistics annual 1995. Geneve: WHO; 1996.
2. Oliver SE, May MT, Gunnell D. International trends in prostate-cancer mortality in the "PSA era." Int J Cancer 2001;92:893-8.
3. Kramer BS, Gohagan J, Prorok PC, Smart C. A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers. Cancer (Phila) 1993;71:589-93.
4. Auvinen A, Rietbergen JBW, Denis LI, Schröder FH, Prorok PC. International Prostate Cancer Screening trial Evaluation Group. Prospective evaluation plan for randomized trials of prostate cancer screening. J Med Screening 1996;3:97-104.
5. Labrie F, Candas B, Cusan L, et al. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Urology 1996;47:212-7.
6. de Koning HJ, Auvinen A, Sanchez AB, et al. Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer Screening trial and the Prostate, Lung, Colorectal and Ovary Cancer trial. Int J Cancer 2002;97:237-44.
7. Hoedemaeker RF, van der Kwast TH, Boer R, et al. Pathologic features of prostate cancer found at population-based screening with a four-year interval. J Natl Cancer Inst (Bethesda) 2001;93:1153-8.
8. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. J Am Med Assoc 1993;270:948-54.
9. Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG, Pileblad E. Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable. J Urol 2003;169:1720-3.
10. Määttänen L, Auvinen A, Stenman U-H, et al. European Randomized Study of Screening for Prostate Cancer: first-year results of the Finnish trial. Br J Cancer 1999;79:1210-4.
11. Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol 1992;23:273-9.
12. Sobin LH, Wittekind C, editors. TNM classification of malignant tumours (international union against cancer). New York: John Wiley & Sons;1997.
13. Oesterling JE. Using PSA to eliminate the staging radio nuclide bone scan. Significant economic implications. Urol Clin N Am 1993;20:705-11.
14. Tabar L, Fagerberg G, Duffy SW, Day NE, Gad A, Grontoft O. Update of the Swedish two county program of mammographic screening for breast cancer. Radiol Clin N Am 1992;30:187-210.
15. American Urological Association. Prostate-specific antigen (PSA) best practice policy. Oncology (Basel) 2000;14:267-86.
16. Smith RA, Cokkinides V, von Eschenbach AC, et al. American Cancer Society guidelines for the early detection of cancer. CA - Cancer J Clin 2002;52:8-22.
17. Yao S-L, Lu-Yao G. Interval after prostate specific antigen testing and subsequent risk of incurable prostate cancer. J Urol 2001;166:861-5.
18. Ross KS, Carter HB, Pearson JD. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. J Am Med Assoc 2000;284:1399-1405.
19. Van der Cruijsen-Koeter IW, van der Kwast TH, Schröder FH. Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam. J Natl Cancer Inst (Bethesda) 2003;95:1462-6.
20. Mäkinen T, Tammela TLJ, Stenman U-H, et al. Family history and prostate cancer screening with prostate-specific antigen. J Clin Oncol 2002;20:2658-63.
21. Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994;330:242-8.
22. Carter HB, Epstein JI, Chan DW, Fozard JL, Pearson JD. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. J Am Med Assoc 1997;277:1456-60.
23. Smith DS, Catalona WJ, Herschman JD. Longitudinal screening for prostate cancer with prostate-specific antigen. J Am Med Assoc 1996; 276:1309-15.